Medikine, Inc.

Medikine, Inc. is a biopharmaceutical company focused on revolutionizing the discovery of oncology, autoimmune disorder, and infectious disease therapeutics through its innovative drug discovery platform. The company's lead product candidate MDK-703, set to commence clinical trials in 2022, is an Fc-fusion protein containing an IL-7 PEPTIKINE, designed to emulate the beneficial properties of IL-7 without the generation of neutralizing antibodies. Additionally, Medikine has identified novel PEPTIKINES that activate the IL-2/15βγc receptor, offering potential for bispecifics with differentiated profiles. The company, founded in 2008, is spearheaded by a team of industry veterans with extensive experience in pioneering drug discovery technology and developing immuno-oncology therapeutics. Medikine aims to advance its pipeline assets through clinical development while seeking partnerships to expand into clinical-stage opportunities. For more details, visit www.medikine.com. Medikine's disruptive drug discovery platform and the potential of its lead product candidate make it an intriguing company for venture capital investment, especially considering its focus on therapeutics for serious diseases. As a prospective investor, it would be valuable to monitor the progress of MDK-703's clinical trials in 2022 and the company's efforts to seek partnerships for further expansion.